Ratings Surperformance

Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB

Ratings ESG MSCI

Ratings Collegium Pharmaceutical, Inc.: Strengths and Weaknesses

Highlights: Collegium Pharmaceutical, Inc.
  • The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
  • Over the last twelve months, the sales forecast has been frequently revised upwards.
  • For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses: Collegium Pharmaceutical, Inc.
  • The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
  • The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
  • The average consensus view of analysts covering the stock has deteriorated over the past four months.

Rating Financials

Collegium Pharmaceutical, Inc. SectorUnited States

Fundamentals

-

Growth

-

Revenue growth

EPS growth

-

FCF growth

-

Profitability

EBITDA Margin

EBIT Margin

Net Margin

-

Capital Efficiency

-

ROA

-

ROCE

-

ROE

-

Financial Health

-

Gearing

-

Leverage

-

Capital Intensity

Balance sheet growth

-

Long Term balance sheet growth

-

Long term revenue growth

Long term EPS growth

-
More ratings

Rating Valuation

Collegium Pharmaceutical, Inc. SectorUnited States

Global Valuation

-

Enterprise Value

-

EV/Revenue

-

EV/EBITDA

-

EV/FCF

-

Equity Valuation

-

P/E

-

PBR

-

Dividend Yield

-

EV/EBIT

-

CAPEX/Revenue

More ratings

Rating Consensus

Collegium Pharmaceutical, Inc. SectorUnited States

Consensus

Analysts' buy/sell recommendations

Analysts' recommendations evolution (1 year)

Analysts' recommendations evolution (4 months)

Analysts' target price

Analysts' target price evolution (1 year)

Analysts' target price evolution (4 months)

Analysts' recommendations evolution (7 days)

Target Price evolution (7 days)

More ratings

Rating Business Predictability

Collegium Pharmaceutical, Inc. SectorUnited States

Visibility

Analysts' coverage

Financial estimates divergence

Analysts' recommendations divergence

Analysts' Target price divergence

Surprise rates

Rating Revisions

Collegium Pharmaceutical, Inc. SectorUnited States

Financial revisions

Revenue revisions (1 year)

Revenue revisions (4 months)

EPS revisions (1 year)

EPS revisions (4 months)

EPS revisions (7 days)

Revenue revisions (7 days)

More ratings

Capi.($) Investor ESG MSCI Fundamentals Financial revisions Global Valuation Visibility Consensus
883M -
BBB
- -
1,119B
A
651B -
BBB
- -
468B
AA
-
374B
AA
302B
AAA
259B
A
238B
A
208B
A
181B
AA
Average 380.07B
AA
Weighted average by Cap.
AA
  1. Stock Market
  2. Stocks
  3. COLL Stock
  4. Ratings Collegium Pharmaceutical, Inc.